SOCS4

Across TCGA pan-cancer cohorts, SOCS4 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SOCS4 data layer compared with 25 for mass-spec protein.

The strongest signal is observed in cholangiocarcinoma (CHOL), where higher SOCS4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SOCS4 expression acts as an unfavorable survival marker.

CHOL, BLCA, and COAD are the cancer types where SOCS4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CHOL	OS	Median	All	0.024	0.728	<.001	36	view →
BLCA	OS	Median	All	0.248	0.720	.026	15	view →
COAD	OS	Median	IV	0.045	0.659	<.001	12	view →
LIHC	DFS	Median	All	0.038	0.556	<.001	12	view →
PRAD	DFS	Median	All	0.080	0.776	<.001	6	view →
SCLC	OS	Median	II,III,IV	0.152	0.777	.038	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

SOCS4–CHOL (OS)

Open the CHOL breakdown →